



November 23, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street
Mumbai - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose disclosure of Related Party Transactions for the half-year ended September 30, 2022.

The above is for your information and dissemination.

Thanking You,

For LUPIN LIMITED

**Rajvardhan
Vishnu Satam**

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, o=Maharashtra,
2.5.4.20=c18d8f9b1d8c2d8f75a093a6f9124b21232ab2f995a7a2ab0747005
375b7, postalCode=400104, cn=Rajvardhan Vishnu Satam, email=rajvardhan@lupin.com,
10405, SERIAL=20221123124056, c=IN, o=Maharashtra, ou=Corporate Identity,
pseudoym=Rajvardhan Vishnu Satam, title=0191,
serialNumber=0191, email=rajvardhan@lupin.com, cn=Rajvardhan Vishnu Satam,
434771123, c=IN, o=Maharashtra, ou=Corporate Identity,
Date: 2022.11.23 12:40:56 +05'30'

Encl: a/a.

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																		
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
89	Lupin Limited		Lupin Inc., USA		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	18.73	18.73	0.00	0.00								
90	Lupin Limited		Lupin Research Inc. USA		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	9.70	9.70	0.00	0.00								
91	Lupin Limited		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare Limited)		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	3.67	3.67	0.00	0.00								
92	Lupin Limited		Lupin Digital Health Limited, India		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	1.23	1.23	0.00	0.00								
93	Lupin Limited		Lupin Investments Pvt. Limited		Entity having significant influence over the company	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.03	0.03	0.00	0.00								
94	Lupin Limited		S. N. Pharma		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Expenses incurred on our behalf reimbursed & Other Reimbursements	2.25	2.25	0.00	0.00								
95	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly-Owned Subsidiary	Investment	0.00	0.00	13.79	13.79								
96	Lupin Limited		Lupin Australia Pty Limited, Australia		Wholly-Owned Subsidiary	Investment	0.00	0.00	33.32	33.32								
97	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly-Owned Subsidiary	Investment	0.00	0.00	32805.56	32805.56								
98	Lupin Limited		Nanomi B.V., Netherlands		Wholly-Owned Subsidiary	Investment	0.00	0.00	50885.21	50885.21								
99	Lupin Limited		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare Limited)		Wholly-Owned Subsidiary	Investment	0.00	0.00	1081.67	1081.67								
100	Lupin Limited		Lupin Oncology Inc., USA		Subsidiary	Investment	0.00	0.00	1127.85	1127.85								
101	Lupin Limited		Zyma Properties Pvt. Limited		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Inter-corporate deposit	21.60	21.60	0.00	0.00								
102	Lupin Limited		Zyma Properties Pvt. Limited		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Inter-corporate deposit	0.00	0.00	29.00	7.40								
103	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly-Owned Subsidiary	Payables	0.00	0.00	717.09	162.84								
104	Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly-Owned Subsidiary	Payables	0.00	0.00	31.95	18.47								
105	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly-Owned Subsidiary	Payables	0.00	0.00	47.93	95.91								
106	Lupin Limited		Lupin Europe GmbH, Germany		Wholly-Owned Subsidiary	Payables	0.00	0.00	2.57	2.31								
107	Lupin Limited		Pharma Dynamics (Proprietary) Limited, South Africa		Wholly-Owned Subsidiary	Payables	0.00	0.00	4.70	3.31								
108	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly-Owned Subsidiary	Payables	0.00	0.00	40.70	14.79								
109	Lupin Limited		Generic Health Pty Limited, Australia		Wholly-Owned Subsidiary	Payables	0.00	0.00	0.61	3.58								
110	Lupin Limited		Lupin Pharma Canada Limited Canada		Wholly-Owned Subsidiary	Payables	0.00	0.00	30.07	48.77								
111	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly-Owned Subsidiary	Payables	0.00	0.00	14.04	15.07								
112	Lupin Limited		Lupin Research Inc. USA		Wholly-Owned Subsidiary	Payables	0.00	0.00	291.42	766.19								
113	Lupin Limited		Novel Laboratories Inc. USA		Wholly-Owned Subsidiary	Payables	0.00	0.00	8.97	102.27								
114	Lupin Limited		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare Limited)		Wholly-Owned Subsidiary	Payables	0.00	0.00	0.00	0.40								
115	Lupin Limited		Lupin Management Inc., USA		Wholly-Owned Subsidiary	Payables	0.00	0.00	96.45	178.30								
116	Lupin Limited		Lupin Digital Health Limited, India		Wholly-Owned Subsidiary	Payables	0.00	0.00	0.00	1.23								
117	Lupin Limited		Shuban Prints		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Payables	0.00	0.00	2.49	0.90								
118	Lupin Limited		Team Lease Services Limited		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Payables	0.00	0.00	0.02	0.02								
119	Lupin Limited		S. N. Pharma		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Payables	0.00	0.00	6.74	2.51								
120	Lupin Limited		Lupin Australia Pty Limited, Australia		Wholly-Owned Subsidiary	Payables	0.00	0.00	1.32	8.31								
121	Lupin Limited		Lupin Inc., USA		Wholly-Owned Subsidiary	Payables	0.00	0.00	35.47	50.98								
122	Lupin Limited		Novel Laboratories Inc. USA		Wholly-Owned Subsidiary	Sale of fixed assets	35.86	35.86	0.00	0.00								
123	Lupin Limited		Dr. Kamal K. Sharma		Non- Executive Director	Sale of fixed assets	3.39	3.39	0.00	0.00								
124	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly-Owned Subsidiary	Fees received against guarantee provided on their behalf	33.19	33.19	0.00	0.00								
125	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly-Owned Subsidiary	Fees received against guarantee provided on their behalf	6.99	6.99	0.00	0.00								
126	Lupin Limited		Nanomi B.V., Netherlands		Wholly-Owned Subsidiary	Fees received against guarantee provided on their behalf	20.22	20.22	0.00	0.00								

Details of Related Parties transactions during the period April 1, 2022 to September 30, 2022										Rs. in Million										
										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
127	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly -Owned Subsidiary	Sale of goods or services	72.47	72.47	0.00	0.00										
128	Lupin Limited		Lupin Inc., USA		Wholly -Owned Subsidiary	Sale of goods or services	8.52	8.52	0.00	0.00										
129	Lupin Limited		Lupin Research Inc. USA		Wholly -Owned Subsidiary	Sale of goods or services	0.17	0.17	0.00	0.00										
130	Lupin Limited		Lupin Oncology Inc., USA		Subsidiary	Sale of goods or services	908.89	908.89	0.00	0.00										
131	Lupin Limited		Novel Laboratories Inc. USA		Wholly -Owned Subsidiary	Purchase of fixed assets	49.55	49.55	0.00	0.00										
132	Lupin Limited		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare Limited)		Wholly -Owned Subsidiary	Purchase of fixed assets	0.04	0.04	0.00	0.00										
133	Lupin Limited		Dr. Kamal K. Sharma		Non- Executive Director	Settlement of liabilities by entity on behalf of related party	3.37	3.37	0.00	0.00										
134	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	Letter of Comfort issued by the Company to the bankers of subsidiary companies	1974.31	1974.31	0.00	0.00										
135	Lupin Limited		Lupin Philippines Inc. Philippines		Wholly -Owned Subsidiary	Payables	0.00	0.00	0.05	0.00										
136	Lupin Limited		Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Receivables	0.00	0.00	264.41	283.37										
137	Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary	Receivables	0.00	0.00	10.60	4.13										
138	Lupin Limited		Laboratorios Grin S.A. de C.V., Mexico		Wholly -Owned Subsidiary	Receivables	0.00	0.00	2.68	1.27										
139	Lupin Limited		Lupin Europe GmbH, Germany		Wholly -Owned Subsidiary	Receivables	0.00	0.00	0.16	0.18										
140	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly -Owned Subsidiary	Receivables	0.00	0.00	245.52	413.10										
141	Lupin Limited		Lupin Australia Pty Limited, Australia		Wholly -Owned Subsidiary	Receivables	0.00	0.00	0.00	0.10										
142	Lupin Limited		Lupin Biologics Limited, India		Wholly -Owned Subsidiary	Receivables	0.00	0.00	0.22	0.00										
143	Lupin Limited		Lupin Digital Health Limited, India		Wholly -Owned Subsidiary	Receivables	0.00	0.00	1.34	2.86										
144	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary	Receivables	0.00	0.00	356.28	664.12										
145	Lupin Limited		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare Limited)		Wholly -Owned Subsidiary	Receivables	0.00	0.00	5.07	4.50										
146	Lupin Limited		Nanomi B.V., Netherlands		Wholly -Owned Subsidiary	Receivables	0.00	0.00	7.84	24.44										
147	Lupin Limited		Lupin Inc., USA		Wholly -Owned Subsidiary	Receivables	0.00	0.00	6842.46	1763.45										
148	Lupin Limited		Lupin Management Inc., USA		Wholly -Owned Subsidiary	Receivables	0.00	0.00	3.10	7.37										
149	Lupin Limited		Lupin Oncology Inc., USA		Subsidiary	Receivables	0.00	0.00	812.57	1794.71										
150	Lupin Limited		Lupin Pharma Canada Limited Canada		Wholly -Owned Subsidiary	Receivables	0.00	0.00	248.36	333.27										
151	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	Receivables	0.00	0.00	12801.67	13621.33										
152	Lupin Limited		Lupin Philippines Inc. Philippines		Wholly -Owned Subsidiary	Receivables	0.00	0.00	270.73	238.18										
153	Lupin Limited		Lupin Research Inc. USA		Wholly -Owned Subsidiary	Receivables	0.00	0.00	30.92	53.84										
154	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly -Owned Subsidiary	Receivables	0.00	0.00	374.35	275.73										
155	Lupin Limited		Multicare Pharmaceuticals Philippines Inc. Philippines		Subsidiary	Receivables	0.00	0.00	52.52	75.54										
156	Lupin Limited		Novel Laboratories Inc. USA		Wholly -Owned Subsidiary	Receivables	0.00	0.00	5.82	39.15										
157	Lupin Limited		Pharma Dynamics (Proprietary) Limited, South Africa		Wholly -Owned Subsidiary	Receivables	0.00	0.00	173.72	179.03										
158	Lupin Limited		Southern Cross Pharma Pty Limited Australia		Wholly -Owned Subsidiary	Receivables	0.00	0.00	0.00	0.35										
159	Lupin Limited		Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	0.00	0.00	0.00	1320.44										
160	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	0.00	0.00	64.65	59.02										
161	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	0.00	0.00	28895.89	35080.03										
162	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	0.00	0.00	5840.19	2056.50										
163	Lupin Limited		Nanomi B.V., Netherlands		Wholly -Owned Subsidiary	Guarantees issued by the Company on behalf of subsidiary company for contractual obligations	0.00	0.00	5075.07	5446.86										
164	Lupin Limited		Lupin Investments Pvt. Limited		Entity having significant influence over the company	Dividend paid	828.78	828.78	0.00	0.00										
165	Lupin Limited		Dr. Anuja Gupta (Daughter of Chairman)		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Dividend paid	2.90	2.90	0.00	0.00										
166	Lupin Limited		Ms. Kavita Gupta (Daughter of Chairman)		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Dividend paid	0.80	0.80	0.00	0.00										
167	Lupin Limited		Dr. Richa Gupta (Daughter of Chairman)		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Dividend paid	0.93	0.93	0.00	0.00										

Details of Related Parties transactions during the period April 1, 2022 to September 30, 2022										Rs. in Million										
										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
						Expenses incurred on our behalf reimbursed & Other Reimbursements														
243	Lupin Atlantis Holdings SA, Switzerland		Lupin Europe GmbH, Germany		Fellow Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements		16.76	0.00	0.00										
244	Lupin Atlantis Holdings SA, Switzerland		Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements		2.29	0.00	0.00										
245	Lupin Atlantis Holdings SA, Switzerland		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements		0.00	0.00	0.00										
246	Lupin Atlantis Holdings SA, Switzerland		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements		0.41	0.00	0.00										
247	Lupin Atlantis Holdings SA, Switzerland		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements		1.59	0.00	0.00										
248	Lupin Atlantis Holdings SA, Switzerland		Lupin Research Inc. USA		Fellow Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements		0.00	0.00	0.00										
249	Lupin Atlantis Holdings SA, Switzerland		YL Biologics Ltd., Japan		Jointly Controlled Entity	Receivables		0.00	20.40	0.00										
250	Lupin Atlantis Holdings SA, Switzerland		YL Biologics Ltd., Japan		Jointly Controlled Entity	Expenses incurred on our behalf reimbursed & Other Reimbursements		4.24	0.00	0.00										
251	Nanomi B.V., Netherlands		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Loan		44.42	606.34	650.76						Loan	4.00%	3 yrs	Unsecured	Business Purpose
252	Nanomi B.V., Netherlands		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Interest received		12.75	0.00	0.00										
253	Nanomi B.V., Netherlands		Multicare Pharmaceuticals Philippines Inc. Philippines		Fellow Subsidiary	Dividend received		125.66	0.00	0.00										
254	Nanomi B.V., Netherlands		Generic Health Pty Limited, Australia		Fellow Subsidiary	Investment		0.00	1188.67	1188.67										
255	Nanomi B.V., Netherlands		Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Payables		0.00	2.30	0.00										
256	Nanomi B.V., Netherlands		Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Investment		0.00	1207.73	1207.73										
257	Nanomi B.V., Netherlands		Pharma Dynamics (Proprietary) Limited, South Africa		Fellow Subsidiary	Investment		0.00	6878.78	6878.78										
258	Nanomi B.V., Netherlands		Multicare Pharmaceuticals Philippines Inc. Philippines		Fellow Subsidiary	Investment		0.00	250.56	250.56										
259	Nanomi B.V., Netherlands		Lupin Mexico S.A. de C.V., Mexico		Fellow Subsidiary	Investment		0.00	52.15	52.15										
260	Nanomi B.V., Netherlands		Lupin Philippines Inc. Philippines		Fellow Subsidiary	Investment		0.00	59.89	59.89										
261	Nanomi B.V., Netherlands		Generic Health SDN. BHD., Malaysia		Fellow Subsidiary	Investment		0.00	9.29	9.29										
262	Nanomi B.V., Netherlands		Lupin Inc., USA		Fellow Subsidiary	Investment		0.00	60232.04	60232.04										
263	Nanomi B.V., Netherlands		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Investment		0.00	1316.71	1316.71										
264	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Loan		0.00	126.33	126.33						Loan	0.75%	2 yrs	Unsecured	Business Purpose
265	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Purchase of goods or services		4.71	0.00	0.00										
266	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Sale of goods or services		17.93	0.00	0.00										
267	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Interest received		0.39	0.00	0.00										
268	Hormosan Pharma GmbH, Germany		Nanomi B.V., Netherlands		Fellow Subsidiary	Receivables		0.00	0.00	0.28										
269	Hormosan Pharma GmbH, Germany		Nanomi B.V., Netherlands		Fellow Subsidiary	Legal and Professional Expenses		0.26	0.00	0.00										
270	Lupin Inc., USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Receivables		0.00	0.08	7.23										
271	Lupin Inc., USA		Lupin Oncology Inc., USA		Fellow Subsidiary	Receivables		0.00	1.13	14.33										
272	Lupin Inc., USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Payables		0.00	0.07	0.00										
273	Lupin Inc., USA		Lupin Oncology Inc., USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		21.95	0.00	0.00										
274	Lupin Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Receivables		0.00	158.50	0.00										
275	Lupin Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Loan		0.00	909.50	909.50										
276	Lupin Inc., USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Sale of goods or services		10.66	0.00	0.00										
277	Lupin Oncology Inc., USA		Lupin Inc., USA		Fellow Subsidiary	Payables		0.00	1.13	14.33										
278	Lupin Oncology Inc., USA		Lupin Management Inc., USA		Fellow Subsidiary	Payables		0.00	0.00	2.74										
279	Lupin Management Inc., USA		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Receivables		0.00	24.34	10.08										
280	Lupin Management Inc., USA		Multicare Pharmaceuticals Philippines Inc. Philippines		Fellow Subsidiary	Receivables		0.00	6.38	8.40										
281	Lupin Management Inc., USA		Laboratorios Grin S.A. de C.V., Mexico		Fellow Subsidiary	Receivables		0.00	13.43	9.96										
282	Lupin Management Inc., USA		Nanomi B.V., Netherlands		Fellow Subsidiary	Receivables		0.00	3.95	9.98										
283	Lupin Management Inc., USA		Generic Health Pty Limited, Australia		Fellow Subsidiary	Receivables		0.00	10.68	2.00										
284	Lupin Management Inc., USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Receivables		0.00	1.08	0.00										
285	Lupin Management Inc., USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Payables		0.00	2.90	0.00										
286	Lupin Management Inc., USA		Generic Health Pty Limited, Australia		Fellow Subsidiary	Sale of goods or services		3.64	0.00	0.00										
287	Lupin Management Inc., USA		Generic Health Pty Limited, Australia		Fellow Subsidiary	Expenses incurred on their behalf recovered		0.51	0.00	0.00										
288	Lupin Management Inc., USA		Laboratorios Grin S.A. de C.V., Mexico		Fellow Subsidiary	Sale of goods or services		18.83	0.00	0.00										
289	Lupin Management Inc., USA		Laboratorios Grin S.A. de C.V., Mexico		Fellow Subsidiary	Expenses incurred on their behalf recovered		2.89	0.00	0.00										
290	Lupin Management Inc., USA		Lupin Oncology Inc., USA		Fellow Subsidiary	Sale of goods or services		6.54	0.00	0.00										
291	Lupin Management Inc., USA		Lupin Oncology Inc., USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		0.31	0.00	0.00										
292	Lupin Management Inc., USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Sale of goods or services		4.35	0.00	0.00										
293	Lupin Management Inc., USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Expenses incurred on their behalf recovered		0.61	0.00	0.00										
294	Lupin Management Inc., USA		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Sale of goods or services		18.23	0.00	0.00										

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																		
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
295	Lupin Management Inc., USA		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Expenses incurred on their behalf recovered		2.48	0.00	0.00								
296	Lupin Management Inc., USA		Multicare Pharmaceuticals Philippines Inc. Philippines		Fellow Subsidiary	Sale of goods or services		16.31	0.00	0.00								
297	Lupin Management Inc., USA		Multicare Pharmaceuticals Philippines Inc. Philippines		Fellow Subsidiary	Expenses incurred on their behalf recovered		2.21	0.00	0.00								
298	Lupin Management Inc., USA		Nanomi B.V., Netherlands		Fellow Subsidiary	Sale of goods or services		8.98	0.00	0.00								
299	Lupin Management Inc., USA		Nanomi B.V., Netherlands		Fellow Subsidiary	Expenses incurred on their behalf recovered		0.64	0.00	0.00								
300	Lupin Pharmaceuticals Inc. USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Sale of goods or services		1.35	0.00	0.00								
301	Lupin Pharmaceuticals Inc. USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Expenses incurred on their behalf recovered		2.09	0.00	0.00								
302	Lupin Pharmaceuticals Inc. USA		Lupin Research Inc. USA		Fellow Subsidiary	Receivables		0.00	4.70	0.00								
303	Lupin Pharmaceuticals Inc. USA		Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Receivables		0.00	0.97	1.30								
304	Lupin Research Inc. USA		Nanomi B.V., Netherlands		Fellow Subsidiary	Sale of goods or services		26.56	0.00	0.00								
305	Lupin Research Inc. USA		Nanomi B.V., Netherlands		Fellow Subsidiary	Receivables		0.00	39.86	27.56								
306	Lupin Pharma Canada Limited Canada		Lupin Inc., USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		0.08	0.00	0.00								
307	Lupin Pharma Canada Limited Canada		Lupin Management Inc., USA		Fellow Subsidiary	Payables		0.00	1.07	2.42								
308	Lupin Pharma Canada Limited Canada		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Payables		0.00	0.96	1.30								
309	Lupin Inc., USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Investment		0.00	610.42	610.42								
310	Lupin Inc., USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Receivables		0.00	0.00	0.00								
311	Lupin Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Receivables		0.00	0.00	153.89								
312	Lupin Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Investment		0.00	769.10	769.13								
313	Lupin Inc., USA		Novel Laboratories Inc. USA		Fellow Subsidiary	Receivables		0.00	0.00	0.00								
314	Lupin Inc., USA		Lupin Management Inc., USA		Fellow Subsidiary	Receivables		0.00	0.00	13.83								
315	Lupin Inc., USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Payables		0.00	11072.40	20809.87								
316	Lupin Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Payables		0.00	0.00	0.00								
317	Lupin Inc., USA		Novel Laboratories Inc. USA		Fellow Subsidiary	Payables		0.00	0.00	1414.60								
318	Lupin Inc., USA		Novel Laboratories Inc. USA		Fellow Subsidiary	Investment		0.00	6172.57	6172.57								
319	Lupin Inc., USA		Lupin Management Inc., USA		Fellow Subsidiary	Payables		0.00	0.00	0.00								
320	Lupin Inc., USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Sale of goods or services		6532.29	0.00	0.00								
321	Lupin Inc., USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Sale of goods or services		70.20	0.00	0.00								
322	Lupin Inc., USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		31.45	0.00	0.00								
323	Lupin Inc., USA		Lupin Management Inc., USA		Fellow Subsidiary	Sale of goods or services		36.29	0.00	0.00								
324	Lupin Inc., USA		Novel Laboratories Inc. USA		Fellow Subsidiary	Sale of goods or services		35.16	0.00	0.00								
325	Lupin Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Sale of goods or services		13.03	0.00	0.00								
326	Lupin Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		20.28	0.00	0.00								
327	Lupin Inc., USA		Lupin Management Inc., USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		18.19	0.00	0.00								
328	Lupin Inc., USA		Novel Laboratories Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		14.22	0.00	0.00								
329	Novel Laboratories Inc. USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		30.98	0.00	0.00								
330	Novel Laboratories Inc. USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Receivables		0.00	0.00	0.62								
331	Novel Laboratories Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		24.09	0.00	0.00								
332	Novel Laboratories Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services		2892.29	0.00	0.00								
333	Novel Laboratories Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services		222.62	0.00	0.00								
334	Novel Laboratories Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Receivables		0.00	1235.70	1414.60								
335	Novel Laboratories Inc. USA		Lupin Management Inc., USA		Fellow Subsidiary	Payables		0.00	0.00	11.82								
336	Lupin Research Inc. USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Payables		0.00	0.00	4.23								
337	Lupin Research Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Payables		0.00	0.00	153.89								
338	Lupin Research Inc. USA		Lupin Management Inc., USA		Fellow Subsidiary	Payables		0.00	0.00	2.65								
339	Lupin Research Inc. USA		Lupin Management Inc., USA		Fellow Subsidiary	Receivables		0.00	0.00	0.00								
340	Lupin Research Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services		517.13	0.00	0.00								
341	Lupin Research Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		193.36	0.00	0.00								
342	Lupin Pharmaceuticals Inc. USA		Lupin Research Inc. USA		Fellow Subsidiary	Receivables		0.00	0.00	4.23								
343	Lupin Pharmaceuticals Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Receivables		0.00	0.00	20809.87								
344	Lupin Pharmaceuticals Inc. USA		Lupin Management Inc., USA		Fellow Subsidiary	Receivables		0.00	0.00	0.00								
345	Lupin Pharmaceuticals Inc. USA		Novel Laboratories Inc. USA		Fellow Subsidiary	Payables		0.00	0.00	0.62								
346	Lupin Pharmaceuticals Inc. USA		Lupin Management Inc., USA		Fellow Subsidiary	Payables		0.00	0.00	5.09								
347	Lupin Pharmaceuticals Inc. USA		Lupin Research Inc. USA		Fellow Subsidiary	Sale of goods or services		4.87	0.00	0.00								
348	Lupin Pharmaceuticals Inc. USA		Lupin Research Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		12.91	0.00	0.00								
349	Lupin Pharmaceuticals Inc. USA		Novel Laboratories Inc. USA		Fellow Subsidiary	Sale of goods or services		8.16	0.00	0.00								
350	Lupin Pharmaceuticals Inc. USA		Novel Laboratories Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		8.17	0.00	0.00								
351	Lupin Pharmaceuticals Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services		37.10	0.00	0.00								
352	Lupin Pharmaceuticals Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		39.04	0.00	0.00								
353	Lupin Pharmaceuticals Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services		6.01	0.00	0.00								
354	Lupin Pharmaceuticals Inc. USA		Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services		58.26	0.00	0.00								
355	Lupin Pharmaceuticals Inc. USA		Lupin Management Inc., USA		Fellow Subsidiary	Sale of goods or services		7.34	0.00	0.00								
356	Lupin Pharmaceuticals Inc. USA		Lupin Management Inc., USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		15.29	0.00	0.00								
357	Lupin Management Inc., USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		2.02	0.00	0.00								
358	Lupin Management Inc., USA		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Sale of goods or services		18.56	0.00	0.00								
359	Lupin Management Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Sale of goods or services		5.93	0.00	0.00								

